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Phase I study to determine the safety, tolerability and
immunostimulatory activity of thalidomide analogue CC-5013 in
patients with metastatic malignant melanoma and other advanced
cancers
JB Bartlett1, A Michael1, IA Clarke1, K Dredge1, S Nicholson1, H Kristeleit1, A Polychronis1, H Pandha1,
GW Muller2, DI Stirling2, J Zeldis2 and AG Dalgleish*,1
1Division of Oncology, Department of Cellular & Molecular Medicine, St George’s Hospital Medical School, Cranmer Terrace, Tooting, London SW17 ORE,
UK; 2Celgene Corporation, Warren, NJ, USA
We assessed the safety, tolerability and efficacy of the immunomodulatory drug, CC-5013 (REVIMIDt), in the treatment of patients
with metastatic malignant melanoma and other advanced cancers. A total of 20 heavily pretreated patients received a dose-escalating
regimen of oral CC-5013. Maximal tolerated dose, toxicity and clinical responses were evaluated and analysis of peripheral T-cell
surface markers and serum for cytokines and proangiogenic factors were performed. CC-5013 was well tolerated. In all, 87% of
adverse effects were classified as grade 1 or grade 2 according to Common Toxicity Criteria and there were no serious adverse
events attributable to CC-5013 treatment. Six patients failed to complete the study, three because of disease progression, two
withdrew consent and one was entered inappropriately and withdrawn from the study. The remaining 14 patients completed
treatment without dose reduction, with one patient achieving partial remission. Evidence of T-cell activation was indicated by
significantly increased serum levels of sIL-2 receptor, granulocyte–macrophage colony-stimulating factor, interleukin-12 (IL-12),
tumour necrosis factor-a and IL-8 in nine patients from whom serum was available. However, levels of proangiogenic factors vascular
endothelial growth factor and basic foetal growth factor were not consistently affected. This study demonstrates the safety,
tolerability and suggests the clinical activity of CC-5013 in the treatment of refractory malignant melanoma. Furthermore, this is the
first report demonstrating T-cell stimulatory activity of this class of compound in patients with advanced cancer.
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CC-5013 is in development for the treatment of a variety of
oncological and inflammatory diseases. The first available
immunomodulatory drug (IMiD), Thalomids (thalidomide), is
approved for the treatment of the cutaneous manifestations of
moderate to severe erythema nodosum leprosum (ENL). Thalido-
mide has also been shown to be a useful drug in a wide range of
other clinical conditions for which there is little other treatment
option (Marriott et al, 1999; Raje and Anderson, 1999). These
include rheumatoid arthritis (Schuler and Ehninger, 1995), the
inflammatory and wasting effects of chronic tuberculosis (Klaus-
ner et al, 1996), Behcet’s disease (Hamuryudan et al, 1998),
Crohn’s disease (Wettstein and Meagher, 1997; Ehrenpreis et al,
1999; Vasiliauskas et al, 1999) aphthous ulcers (Youle et al, 1989;
Alexander and Wilcox, 1997; Jacobson et al, 1997), cachexia
(wasting) associated with HIV infection (Sharpstone et al, 1995;
Reyes-Teran et al, 1996) and AIDS-related Kaposi’s sarcoma (Fife
et al, 1998). There is also a wide body of evidence from large-scale
clinical trials showing the effectiveness of thalidomide as a
treatment for refractory or relapsed multiple myeloma (MM)
(Singhal et al, 1999; Hideshima et al, 2000; Juliusson et al, 2000;
Kneller et al, 2000; Zomas et al, 2000), and this extends to the
treatment of a number of other tumours (Eisen et al, 2000; Fine
et al, 2000; Gutheil and Finucane, 2000; Patt et al, 2000; Tseng et al,
2001; Eisen, 2002).
Immunomodulatory drug analogues are able to costimulate T
cells (Haslett et al, 1998; Corral et al, 1999) and are highly
antiangiogenic (Dredge et al, 2002a). The ability to costimulate T
cells has been associated with an increased Th1-type cytokine
response and suggests that in certain clinical settings, IMiD
analogues are likely to act as adjuvants to promote T-cell
responses, thereby contributing to antitumour activity in vivo. In
this regard, IMiDs have been shown to augment antitumour
responses in vivo, leading to long-term protection from tumour
challenge (Dredge et al, 2002b). Antiangiogenic activity has
provided the rationale for the use of this class of compound as
anticancer agents and, although unproven, this has often been
linked to thalidomide’s teratogenicity. However, the lead IMiD,
CC-5013, has been shown to be both nonteratogenic and
antiangiogenic in animal models.
The clinical development of the IMiDs has been initiated with
the use of CC-5013 in MM (Marriott et al, 2001; Richardson et al,
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2001; Zangari et al, 2001). This compound has recently completed
a phase I clinical trials programme in which it was found to be safe
and well tolerated. Furthermore, a report of clinical efficacy of CC-
5013 in MM patients has recently been published (Richardson et al,
2002), although T-cell costimulation has not been demonstrated in
vivo. We therefore conducted a phase 1 study of CC-5013 in
patients with metastatic malignant melanoma with treatment
administered according to an accelerated titration design with
intrapatient dose escalation (modified from Simon et al, 1997).
This disease has a median survival of 6 –9 months and current
systemic therapy can induce complete durable responses in only a
small minority of patients (Atkins, 1997). Current chemother-
apeutic options offer a very poor response rate of 14– 20% and
immunotherapy, for example interleukin (IL)-2 and interferon-a
(IFN-a) have produced good responses in only a small number of
patients.
In this study, we have assessed the safety, tolerability and
clinical effects of CC-5013 during the treatment of 20 patients with
metastatic malignant melanoma and other advanced cancers
(Table 1). We have also sought evidence of immunostimulatory
and antiangiogenic effects by assessing multiple serological factors
and changes in peripheral blood T-cell markers.
MATERIALS AND METHODS
Patient selection
Patients were recruited from a single oncology centre according to
the following eligibility criteria: histologically or cytologically
proven stage IV metastatic melanoma (n¼ 13), unresectable
adenocarcinoma of pancreas (n¼ 2), renal cell carcinoma
(n¼ 1), ductal carcinoma of the breast (n¼ 1), squamous cell
carcinoma of the lung (n¼ 1), carcinoid (n¼ 1); age over 18 years;
clinical or radiological evidence of disease progression in the 3
months prior to trial entry; life expectancy of over 2 months;
adequate baseline organ function; and minimum body weight of
50 kg. Previous treatment with chemotherapy or radiotherapy was
allowed with the exception of prior radiotherapy to the brain. For
all patients, there was no known hypersensitivity to thalidomide or
similar drugs and no previous anticancer therapy or experimental
treatment for 30 days prior to study entry (for pancreatic patients,
no concomitant chemotherapy). Women were excluded from the
study if pregnant, lactating or not using adequate contraception.
All patients gave written informed consent prior to participation in
the study. The study protocol was approved by the local research
ethics committee (LREC) and was conducted according to ICH
good clinical practice and in accordance with the declaration of
Helsinki.
Treatment and assessment
CC-5013 was manufactured by Penn pharmaceuticals (Tredegar,
Wales, UK) and supplied by Celgene Corporation (Warren, NJ,
USA). Before initiating therapy, patients were subject to a complete
medical history, physical examination and baseline evaluation of
signs and symptoms, including full blood counts and a detailed
neurological examination. These were repeated at weekly intervals
during the study period and also at the end of the study. CC-5013
was taken in tablet form each evening and blood samples
were collected at approximately the same time of the day at each
visit. Therefore, analysis of serum cytokines and T-cell subsets
was undertaken at a constant interval relative to the CC-5013
administration.
The treatment was administered according to accelerated
titration design with intrapatient dose escalation (modified from
Simon et al, 1997). All patients were treated with 5 mg day1 CC-
5013 for 1 week with the dose escalating to 10 mg day1 at week 2,
25 mg day1 at week 3 and 50 mg day1 at week 4. The study
treatment was terminated after 4 weeks; however, patients were
allowed to continue on the final dose subject to tolerance and
response. Treatment beyond 28 days was administered on a named
patient basis and patients continued to be regularly assessed for
toxicity and response.
The assessment of safety and tolerability of the study drug was
based on the evaluations of the clinical laboratory tests, measure-
ments of vital signs and the occurrence of adverse events during
the study. The toxicity of the study drug was evaluated by means of
the NCI-Common Toxicity Criteria (http://ctep.info.nih.gov/re-
porting/ctc.html).
Evaluation of tumour response was performed following 4 weeks
of treatment with CT scan and measurement of visible skin lesions.
Response was classified as per WHO criteria.
Analysis of serological factors
Blood was collected into serum separator tubes and left to clot for
B30 min. Tubes were spun at 950 g for 10 min and serum was
collected. Sera were frozen in aliquots at 701C until assayed for
sIL-2 receptor, IL-2, IL-12, tumour necrosis factor-a (TNF-a), IFN-
g, granulocyte– macrophage colony-stimulating factor (GM-CSF),
vascular endothelial growth factor (VEGF), IL-8 and basic fibro-
blast growth factor (b-FGF) by ELISA. Standard absorbance
(405 nm) of duplicate wells was used to calculate the concentration
of cytokine/receptor levels.
Phenotypic analysis of T cells
Heparinised venous blood was collected into sodium heparin
vacutainers and surface stained (for 15 min at room temperature
(RT)) with the following fluorochrome-conjugated monoclonal
antibodies: anti-CD4 PerCP (Clone SK7; Becton Dickinson
Immunocytometry Systems, BDIS, Oxford, UK) or anti-CD8 PerCP
(SK1; BDIS) with anti-CD45RA FITC (L48;BDIS) and anti-CD45RO
PE (UCHL-1;BDIS) plus appropriate isotype matched and com-
pensation controls. Red blood cells were lysed with 2 ml 1 FACS
Lysing Solution (BDIS; 10 min, RT), samples were spun down
(500 g, 5 min) and the cell pellet resuspended in 200ml CellFix
(BDIS) for analysis. PBMC were surface stained (30 min, 41C) with
anti-CD4 or anti-CD8 PerCP FITC (SK11; BDIS) and anti-CD45RO
PE plus appropriate isotype matched and compensation controls.
Upon flow cytometric analysis, lymphocytes were gated on
forward scatter (FSC) vs side scatter (SSC) properties and PerCP-
positive T-cell subsets were displayed as two-colour dotplots. For
each sample, 10 000 lymphocytes were acquired on a Becton
Dickinson FACScan using CellQuestt software and analysed using
EXPO32t (Beckman Coulter).
Statistical analysis
Serological and cell surface data comparisons between groups were
examined by the Mann–Whitney U-test. The statistics were
performed using GraphPad InStat 3 software.
RESULTS
Patient characteristics
The study recruited 20 patients, 13 with stage IV malignant
melanoma, two with unresectable adenocarcinoma of the pancreas,
one case of renal cell carcinoma, one of ductal carcinoma of the
breast, one carcinoid and one patient with squamous cell
carcinoma of the lung. (see Table 1 for patient details). In all, 12
patients were male and eight female. Age varied between 16 and 80
years with a median age of 51.5 years. The 16-year-old patient was
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Table 1 Patient details: possible/probable CC-5013-related adverse effects
Patient
no.
Age (years)/
sex Disease Stagea Site Previous treatment Responseb
Completed/
withdrew
Days on study/
maximum dose
(mg)
Samples for in
vitro analysis
1 45/F Malignant melanoma IVabc Right ileoinguinal area Cancervax trial PD Completed 28/50 No
2 28/F Malignant melanoma IVabc Right thigh Dacarbazine (three cycles); peptides
(melanA, gp100, tyrosinase) and IL-2
SD; partial response
of liver
Completed 28/50 No
3 58/M Malignant melanoma IVabc Lower abdomen Dacarbazine; radiotherapy PD Progressed 14/10 No
4 44/F Malignant melanoma IVa Abdomen Adjuvant interferon SD; minor response
of abdominal nodes
Completed 28/50 No
5 16/M Malignant melanoma IVac Right temporal region Adjuvant interferon PD; minor response of
small cutaneous lesion
Completed 28/50 No
6 56/F Malignant melanoma IVabc Vulva Chemotherapy; bilateral groin
radiotherapy
SD Completed 28/50 No
7 31/M Malignant melanoma IVabc Left upper chest Debulking surgery; peptide (triple)
and IL-2; dacarbazine; vindesine X3
SD; minor response
of subcutaneous lesion
Completed 28/50 Yes
8 80/M Malignant melanoma IVab Right side of neck Treosulphan (six cycles) PD Completed 28/50 Yes
9 48/M Malignant melanoma IVa Left foot BCG (two doses) SD; minor response
of cutaneous nodules
Completed 28/50 Yes
10 56/F Malignant melanoma IVac Breast Vinflunine; radiotherapy PD Completed 28/50 No
11 23/M Malignant melanoma IVabc Abdomen Adjuvant interferon; radical
radiotherapy
PD Progressed 24/50 Yes
12 51/M Malignant melanoma IVac Right thigh Carboplatin, dacarbazine, vincristine,
vinblastine & vindesine
SD Completed 28/50 Yes
13 64/M Malignant melanoma IVabc Right chest wall, right
lower eyelid, lips
Multiple surgery only PR, CT & complete
subcutaneous response
Completed 28/50 Yes
14 52/M Adenocarcinoma of the
Pancreas
IV Pancreas & portal vein M. vaccae; retinoic acid & gemcitabine PD; minor response
serum CA19.9
Completed 28/50 Yes
15 47/M Carcinoid IV Multiple carcinoid
tumours
Radiotherapy; 5-fluorouracil & folinic
acid; interferon; etoposide & cisplatin;
thalidomide
N/E entered
inappropriately
Withdrew 14/10 No
16 34/M Adenocarcinoma of the
Pancreas
IV Head of pancreas Gemcitabine & tomudex PD Completed 28/50 Yes (ELISA only)
17 55/F Renal cell carcinoma IV Left kidney Interferon; bryostatin; thalidomide;
radiotherapy
N/E withdrew due
to adverse effects
Withdrew 16/10 No
18 65/F Ductal carcinoma of
the breast
II Breast Mitozantrone, methotrexate &
mitomycin; cyclophosphomide
methotrexate & 5-fluorouracil;
megace; 5-fluorouracil, epirubicin &
cyclophosphomide; herceptin;
tamoxifen; radiotherapy
N/E withdrew due to
generalised weakness
Withdrew 14/10 No
19 66/M Squamous cell
carcinoma of the lung
IV Right lung Mitomycin, winblastine sulphate &
cisplatin; radiotherapy
PD Progressed 26/25 No
20 66/F Adenocarcinoma of the
lung
III Left lung Radiotherapy; mitomycin, vinblastine
& cisplatin
PD Completed 28/50 Yes
aStaging: a, skin, subcutaneous tissue, lymph node metastases; b, lung and gastrointestinal metastases; c, other sites including liver, bone and brain metastases. bResponse: PR¼ partial response; SD¼ static disease; PD¼ progressive
disease; N/E¼ nonevaluable.
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recruited to the study following thorough discussion and
agreement of the patient, his family and study investigators.
In total, 14 patients received the full 28 days of CC-5013 with no
need for dose reduction. Three patients developed PD while on the
study drug and did not complete treatment. One patient
discontinued after 14 days, one after 24 days and one after 26
days. Three patients were nonevaluable due to withdrawal of
consent to the study, two after 14 days and one after 16 days.
Toxicity
Seven patients developed serious adverse events, none of them
thought to be associated with the study drug. Patient 1 developed
anaemia, requiring blood transfusion, as well as chest infection.
Anaemia was most likely related to heavy bone marrow infiltration
and disseminated disease. Following treatment of the infection, the
patient completed the study. Patient 3 developed shortness of
breath, which was due to accumulation of pleural effusion followed
by chest infection and progressive disease. This patient was
withdrawn from the study after 14 days of treatment. Patient 11
suffered dehydration and subsequent renal failure associated with
poor performance status and disease progression. The patient was
withdrawn from the study after 24 days. Patient 15 had prior spinal
disease and was hospitalised due to spinal cord compression. The
patient was withdrawn after 14 days and the overall impression
was that the patient was entered inappropriately as he was not able
to adhere to the study protocol. Patient 17 experienced a series of
adverse events, mostly diarrhoea, abdominal pain and paraesthe-
sia; none of those were more than grade 2, but he withdrew his
consent to the study drug. Patient 19 was admitted to hospital in
an acute confusional state, caused by a collapsed lung and
increased dyspnoea. The patient was withdrawn from the study at
day 26 and was admitted to a hospice. Patient 20 was hospitalised
with worsened haemoptysis and dyspnoea but completed the
study.
For 36% of the adverse effects, toxicity was classified as grade 1,
51% as grade 2, 8% as grade 3 and 5% as grade 4. There were
several cases of grade 1 and 2 toxicity, some of them possibly
associated with CC-5013 (see Table 2). The most common were:
paraesthesia, altered taste, papular, itchy rash, fatigue, nausea,
poor appetite and vomiting. There was no evidence that
somnolence is a problem for patients taking CC-5013. Apart from
mild paraesthesia, there was no evidence of any neurological
defects. Evidence of haematological toxicity included three patients
who developed thrombocytopaenia and one who developed
neutropaenia while on the study. There was no evidence for any
biochemical toxicities in association with CC-5013 treatment.
Evidence of clinical efficacy
Partial response (PR) was documented in one out of 20 patients
(5%). Five patients had stable disease (SD) (25%) and 11 patients
developed progressive disease (PD) (60%). There were no
complete responses and three patients were not evaluable (patients
17 and 18 withdrew consent and patient 15 was entered
inappropriately). Two of the patients developed a mixed response.
Patient 2 had a decrease in the size of mediastinal mass and skin
lesions but an increase in the size of liver deposit, and patient 14
had stable para-aortic lymphadenopathy but an increase in the
number of lung and liver deposits.
Some patients developed minor responses that did not classify
as PR but with a definite decrease in the size of visceral lymph
nodes (patient 4), subcutaneous nodules (patient 7) and cutaneous
Table 2 Adverse events reported during CC-5013 treatment
Patient Graded diagnosis
NCI toxicity
grade
Causal relationship to
REVIMID treatment
2 Nausea and Vomiting Grade 2 Remote
Fatigue Grade 2 Possible
Altered taste Grade 2 Possible
Hot flushes Grade 1 Possible
Occasional cramps Grade 1 Possible
4 Papular rash Grade 1 Possible
6 Papular rash Grade 2 Possible
8 Cramps Grade 1 Possible
Fatigue Grade 2 Possible
13 Altered taste Grade 1 Possible – although there
is a local lesion
16 Jaundice Grade 2 Remote
17 Numbness Grade 2 Possible
18 Fatigue Grade 2 Possible
20 Macular rash Grade 1 Probable
Figure 1 Evidence of clinical response during CC-5013 treatment. (A)
Patient SR9 exhibited extensive nodular cutaneous disease over his left
thigh. Following treatment (B) lesions became flattened and attenuated.
(C) Patient PB13 shows mediastinal mass (arrowed) on CT scan which is
reduced (D) after treatment.
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disease (patient 9) (Figure 1). In all, 10 patients continued CC-5013
at the final dose (50 mg) on a named patient basis with static
disease and a good quality of life. These patients continued on CC-
5013 for a mean of 3.5 months prior to disease progression. One
patient continued on CC-5013 at 50 mg for 8 months during which
time there was a minor response of pulmonary secondaries.
Effect on immunologic and proangiogenic serum factors
We detected increased levels of GM-CSF, TNF-a (both nine out of
nine), sIL-2 receptor (eight out of nine) and IL-12 (seven out of
nine) in the serum of patients after CC-5013 treatment compared
to pretreatment levels (Figure 2). Available serum samples from
nine patients were assessed. Median sIL-2 receptor: baseline,
710 pg ml1; follow-up, 1294 (*P¼ 0.0005). Median GM-CSF:
baseline, 0 pg ml1; follow-up, 4.13 (*P¼o0.0001). Median TNF-a:
baseline, 2.02 pg ml1; follow-up, 3.63 (*P¼ 0.0056). Median IL-12:
baseline, 1.1 pg ml1; follow-up 9.4 (*P¼ 0.032). We were unable to
detect IL-2 or IFN-g in any of the serum samples.
We also assayed serum to determine effects on the levels
of proangiogenic factors (Figure 3). Median VEGF: baseline,
258 pg ml1; follow-up, 207 (NS, P¼ 0.566). Median b-FGF: base-
line, 1.44 ng ml1; follow-up, 1.4 (NS, P¼ 0.427). Median IL-8:
baseline, 11 pg ml1; follow-up, 32 (*P¼ 0.047).
Effect on peripheral blood T-cell CD45 isoform expression
We determined the expression of CD45 isoforms (CD45RA and
CD45RO) on peripheral CD4þ and CD8þ T cells before CC-5013
treatment and at follow-up (at weeks 4 and 5). Figure 4 shows clear
trends towards decreased CD45RA expression on both T-cell
subsets in conjunction with increased expression of CD45RO.
However, significance is only reached during analysis of decreased
CD45RA expression on CD4þ cells. Median percentage CD45RA
expression on CD4þ cells: baseline, 28.4%; follow-up, 3.5%
(*P¼ 0.003). Median CD45RO expression: baseline, 62.8%; follow-
up, 83.6% (NS, P¼ 0.105). Similar results are seen with CD8þ
cells. Median CD45RA expression: baseline, 42.4%; follow-up,
14.7% (*P¼ 0.049). Median CD45RO expression: baseline, 35.4%;
follow-up, 73.51% (NS, P¼ 0.065).
DISCUSSION
Disseminated malignant melanoma is a chemoresistant tumour
with very poor prognosis. However, immunotherapy in advanced
disease can offer durable responses and a greater understanding of
the immune mechanisms involved may in the future offer better
treatment for a wider group of patients. This study is the first to
show the use of CC-5013 in patients with solid tumours, which
include 13 patients with advanced melanoma. Despite the fact that
clinical response was not the primary end point of the study and
that the patients had not responded to prior therapy, we found
clear evidence of drug activity in rapidly progressing malignant
melanoma with one PR and two minor responses of visceral
disease. Responses were noted in small volume cutaneous and
subcutaneous disease. However, there was no correlation between
clinical response and disease volume; the one PR occurred in a
patient with relatively high volume visceral disease. It was also
noted that patients subjectively felt better after commencing
treatment. There was no therapeutic effect in other solid tumours
treated, although three out of six patients were nonevaluable due to
withdrawal or disease progression. Overall, it would appear that
CC-5013 is capable of inducing antitumour activity at the doses
tested and that static disease can be maintained even if only a
minor response has been achieved.
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Unfortunately, due to the small numbers of patients for whom
immunological parameters could be measured, it was impossible
to correlate the data with clinical response. However, we have
found that irrespective of clinical response, there is strong
evidence of immunological activation in all nine patients from
whom samples were available for analysis. We assessed serum
cytokine levels for evidence of immune activation. While serum
levels of IL-2 and IFN-g remained beneath the detection limit of
the assays employed in the study, there were significant and
consistently increased levels of sIL-2 receptor (in eight out of nine
patients), providing evidence of T-cell activation. The strong
induction of GM-CSF production by CC-5013 in all nine patients is
further evidence of immune activation and is likely to lead to the
stimulation and increased functional capacity of monocytes/
macrophages and dendritic cells (Armitage, 1998), thereby
potentially boosting the presentation of tumour antigens. The
clinical use of recombinant GM-CSF as a cancer immunotherapy
has led to reports demonstrating its benefits in the treatment of
patients with melanoma (Armitage, 1998; Spitler et al, 2000).
The induction of GM-CSF may explain the significantly increased
levels of TNF-a and IL-12 in these patients. These observations are
consistent even in the serum of patients with rapidly progressing
disease that did not respond clinically to CC-5013. Increased
production of TNF-a and IL-12 by antigen-presenting cells is likely
to drive Th1-type immune responses and enhance antitumour
immunity. We have previously shown that the strong induction of
TNF-a in ex vivo cultures correlates with a better prognosis in
patients with colorectal cancer (Heriot et al, 2000).
Immunological activation was also assessed by the analysis of
surface expression of CD45 isoforms on CD4þ and CD8þ T cells.
The CD45RAþ T-cell phenotype represents nonactivated and
mainly naı¨ve cells. Upon activation, truncation of the CD45RA
isoform exposes the CD45RO epitope. Our results show that there
is a remarkably consistent and extensive shift in T-cell expression
of CD45RA at baseline to CD45RO during treatment with CC-5013
(Figure 3). However, due to limited patient numbers, only the
decrease in CD45RA expression reaches statistical significance.
This apparent T-cell activation is evident on both CD4þ and
CD8þ populations, supporting previous in vitro data showing
that IMiDs are able to costimulate both T-cell subsets (Marriott
et al, 2001). The total lymphocyte counts were generally increased
in this patient group (data not shown), indicating that apoptosis of
CD45RAþ cells is unlikely to account for the relative decrease in
this population.
Our data suggest that CC-5013 is able to boost Th1-type cellular
immunity and provide an environment for the generation of an
antitumour response. Support for this concept has been obtained
in a vaccination model of colorectal cancer in which another IMiD
was shown to generate a protective and long-lasting antitumour
response in vivo (Dredge et al, 2002b).
The serological changes observed in our study indicate that low-
dose therapy is able to provide a significant immunological
stimulus. In the context of tumour immunity, this may help to
overcome the anergy associated with advanced cancer patients and
boost cellular immune responses. It is worth noting that the
progressive nature of disease in this patient group means that
while immunological activation is seen in all patients, it is
remarkable to also observe clinical responses and static disease
in some patients. In this regard, it is possible that a correlation
between immunological and clinical responses may become
apparent during the treatment of patients with less advanced
disease. The possibility that CC-5013 may boost previously
induced immunity is suggested by the fact that five patients with
minor responses and static disease had previously been given some
form of immunotherapy, such as melanoma peptides or IL-2.
We have observed that CC-5013 is antiangiogenic using in vitro
assay systems (Dredge et al, 2002a). Therefore, it is possible that
this compound may also act in vivo to reduce the formation of new
blood vessels, thereby inhibiting metastasis and preventing
tumour growth. During our assessment of serum proangiogenic
factors, we found that although levels of the neutrophil chemoat-
tractant IL-8 were increased, VEGF and b-FGF were relatively
unchanged. Interestingly, thalidomide has also been shown to have
no effect on serum VEGF and b-FGF during the effective treatment
of patients with multiple myeloma (Neben et al, 2001). Although
other factors may also be important during angiogenesis, these
results suggest that the T-cell costimulatory activity of CC-5013
(and perhaps thalidomide) may be of greater importance during
the advanced cancer setting. Other evidence in MM patients
suggests that natural killer (NK) cell activity may be important
(Davies et al, 2001) and we have noted increased NK cell numbers in
some patients after CC-5013 treatment (unpublished observation).
The possibility that CC-5013 can enhance the effect of prior or
subsequent treatments cannot be ruled out. Prior immunotherapy,
whether successful or not, may contribute to the immunostimu-
latory properties of CC-5013 and its antiangiogenic properties may
enhance responses to radiotherapy and chemotherapy. Future
studies will need to take these potential interactions into account.
In conclusion, CC-5013 is safe, well tolerated and has some clinical
benefit and immunological effects in the treatment of patients with
refractory malignant melanoma and supports the continuing
clinical development of this exciting class of compounds.
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Figure 4 Effect of CC-5013 treatment on the CD4þ and CD8þ T-
cell surface expression of CD45 isoforms. Data are expressed as
percentage expression on cells’ pretreatment (baseline) and at follow-up
(4–5 weeks after starting treatment). For CD4þ cells: CD45RA
expression; *P¼ 0.003. CD45RO expression; NS, P¼ 0.105. For CD8þ
cells: CD45RA expression; *P¼ 0.049. CD45RO expression; NS,
P¼ 0.065.
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